Great Report on Optiscan Imaging, page-5

Here is the insight I like from the report, as I maintain the cheapest way for Zeiss to get the patents is to buy the company:

"Zeiss is a well-heeled company. The first thing to note about Zeiss is that it has the scale to help establish live micro-imaging in brain surgery as well as more broadly in general surgery and in diagnostics. As we noted above, the company enjoyed FY16 revenue of €1.09bn and EBIT of €154m. Its current market capitalisation on Xetra is about €3.77bn45.

Zeiss needs new growth for its microsurgery business. In the year to September 2016 Zeiss only grew its microsurgery business by 1.3% at the revenue line. Adjusted for currency effects, the business declined during the year by 0.9%. There was year-on-year growth in the December 2016 quarter, but only 0.2% in constant currency terms. The Pentero product line, now about 12 years old, may be well regarded in the marketplace but it is always in danger of losing ground to competitors with lower-priced products such as Leica. We believe that Zeiss is interested in the neurosurgery CLE product from Optiscan as a way of maintaining its lead in the surgical microscopes segment".